Search by Drug Name or NDC
NDC 47426-0302-02 ZYNRELEF 300; 9 mg/10.5mL; mg/10.5mL Details
ZYNRELEF 300; 9 mg/10.5mL; mg/10.5mL
ZYNRELEF is a INFILTRATION SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Heron Therapeutics, Inc.. The primary component is BUPIVACAINE; MELOXICAM.
Product Information
| NDC | 47426-0302 |
|---|---|
| Product ID | 47426-302_ecef2459-9a3e-4a90-b95b-75b94ead9cf1 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | ZYNRELEF |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | BUPIVACAINE and MELOXICAM |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SOLUTION |
| Route | INFILTRATION |
| Active Ingredient Strength | 300; 9 |
| Active Ingredient Units | mg/10.5mL; mg/10.5mL |
| Substance Name | BUPIVACAINE; MELOXICAM |
| Labeler Name | Heron Therapeutics, Inc. |
| Pharmaceutical Class | Amide Local Anesthetic [EPC], Amides [CS], Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Local Anesthesia [PE], Nonsteroidal Anti-inflammatory Drug [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA211988 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 47426-0302-02 (47426030202)
| NDC Package Code | 47426-302-02 |
|---|---|
| Billing NDC | 47426030202 |
| Package | 1 CARTON in 1 KIT (47426-302-02) / 1 VIAL, SINGLE-DOSE in 1 CARTON (47426-302-04) / 10.5 mL in 1 VIAL, SINGLE-DOSE (47426-302-06) |
| Marketing Start Date | 2021-07-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |